Chemical Technology, Science and Research

Lithium batteries whitepaper

December 25, 2022

Lithium batteries
Founded in 1903, Brookes Bell is a leading multi-disciplinary technical and scientific consultancy serving the marine and energy sectors. We investigate, troubleshoot and advise on a broad range of marine and energy matters and enjoy a reputation.

Spotlight

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive clinical data in Phase 2 studies evaluating anabasum for the treatment of diffuse cutaneous systemic sclerosis and for the treatment of cystic fibrosis. Additionally, anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis with a 12-month open-label extension, and another Phase 2 study in systemic lupus erythematosus is scheduled to commence in H2 2017.

OTHER WHITEPAPERS
news image

Analysis of Hand Sanitizers to Support Label Claims

whitePaper | April 30, 2021

At the height of the first wave of the COVID-19 pandemic, consumers around the world experienced a supply shortage related to alcohol-based hand sanitizer. As new producers entered the market, and existing manufacturers sought to ramp-up production to meet the growing demand, lower grades of ethanol and isopropanol (IPA) started to appear on the market. To ensure the safety and efficacy of hand sanitizer products, it is recommended that manufacturers test their products to ensure appropriate levels of active ingredients, as well as a means of ensuring label-claim accuracy. In this application note, an efficient and simple, “dilute and shoot” method for the analysis of IPA and ethanol in hand sanitizer products is detailed. With a run-time of only 5.36 minutes per sample, this method is ideal for operations requiring fast turnaround times that won’t disrupt the production of their products.

Read More
news image

Foil Fluid Flow Frustrations

whitePaper | December 9, 2022

The International Society of Automation (ISA) working group responsible for ISA TR 96.05.01 2008 edition on partial stroke testing of automated valves published an update to the original technical report.

Read More
news image

Tech Trends 2022

whitePaper | December 21, 2022

Over the past two years, the world has been reeling from the shock of the pandemic, and we are now collectively trying to navigate to our “next normal.” Those of us on the Tech Trends team believe that this represents the opportunity to engineer a better future—not to just.

Read More
news image

Decarbonization Investment: Opportunities and Implications for EPCs

whitePaper | November 3, 2022

As sustainability targets drive the energy industry towards a net zero future and energy security concerns intensify, companies are challenged to meet these competing demands within financial and workforce restraints.

Read More
news image

chemicals Evolution of a digital twin with an ethylene plant as an example

whitePaper | January 17, 2020

A digital twin of a process plant as an integrated concept covers three core points: The digital twin of the product, the digital twin of the production plant and the digital modeling of the performance of the product and production. The functional scope of a digital twin essentially depends on its purpose. In the process industry, this can be everything from the safety analysis, product simulation or the optimization of the production process, right up to economic benefit formulation.

Read More
news image

Global Minimum Transparency Standard (GMTS)for hazardous chemicals in products

whitePaper | September 20, 2022

This white paper presents the case for a global standard requiring disclosure of hazardous chemicals used in a product in international trade.

Read More

Spotlight

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive clinical data in Phase 2 studies evaluating anabasum for the treatment of diffuse cutaneous systemic sclerosis and for the treatment of cystic fibrosis. Additionally, anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis with a 12-month open-label extension, and another Phase 2 study in systemic lupus erythematosus is scheduled to commence in H2 2017.

Events